Major strengths of our study were reduced outcome misclassification through use of five markers to identify breast cancer subtypes (ER, PR, HER2, HER1 and CK5/6) and linkage of established datasets to allow for a relatively large study for assessing this association. Here, ERBB2 is linked to breast cancer.